PKC-412 CAS: 120685-11-2
MF: C35H30N4O4
MW: 570.64
A broad spectrum tyrosine kinase inhibitor.

PKC-412 (CAS 120685-11-2)

PKC-412 | CAS 120685-11-2 is rated 5.0 out of 5 by 1.
  • y_2021, m_7, d_26, h_19
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.18
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_200691, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 117ms
  • REVIEWS, PRODUCT
loading
5
1
4
0
3
0
2
0
1
0
Alternate Names: Midostaurin; 4'-N-benzoylstaurosporine; PKC412
Application: PKC-412 is a broad spectrum tyrosine kinase inhibitor
CAS Number: 120685-11-2
Purity: ≥96%
Molecular Weight: 570.64
Molecular Formula: C35H30N4O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).
loading

PKC-412, a staurosporine derivative, has been shown to possess antiproliferative characteristics via inhibition of PKC (protein kinase C), Flk (kinase insert domain receptor), and c-kit. This compound has been shown to cause an increase in the G2/M phase of the cell cycle related to polyploidy, enhanced sensitivity to ionizing radiation, and apoptosis. Additionally, PKC-412 has been reported to inhibit Flt-3/Flk-2 tyrosine kinase which consequentially causes induced G1 arrest and apoptosis of Ba/F3 cell lines. Other experiments have noted that this agent demonstrates the ability to increase endothelial nitric oxide (NO) synthase expression and NO production in cultured human endothelial cells. PKC-412 is an inhibitor of c-Src, Cdk1, cyclin B, EGFR, Flk-1, Flt-1, PDGFR-β, PKA, PKC α, PKC β, PKC γ, PKC δ, PKC η, Fgr and Syk.


References

1. Fabbro, D., et al. 2000. Anticancer Drug Des. 15: 17-28. PMID: 10888033
2. Weisberg, E., et al. 2002. Cancer Cell. 1: 433-443. PMID: 12124173
3. Stone, R.M., et al. 2005. Blood. 105: 54-60. PMID: 15345597
4. Li, H., et al. 2005. Nitric Oxide. 12: 231-236. PMID: 15890550
5. Chen, J., et al. 2005. Oncogene. 24: 8259-8267. PMID: 16091734

Physical State :
Solid
Solubility :
Soluble in DMSO (15 mg/ml), MDC (10 mg/ml), methanol (5 mg/ml), 100% ethanol (2.5 mg/ml), and DMF (20 mg/ml).
Storage :
Store at -20° C
Density :
1.48 g/cm3
Refractive Index :
n20D 1.77
IC50 :
MV4-11 (Myeloid leukemia cells): IC50 = 12 nM (human); FLT3 ITD mutant autophosphorylation: IC50 = 13 nM (human RS4-11 cells); Tyrosine-protein kinase receptor FLT3: IC50 = 15 nM (human)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
Merck Index :
14: 6185
MDL Number :
MFCD10687105
SMILES :
C[[email protected]@]12[[email protected]@H]([[email protected]@H](C[[email protected]@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

PKC-412 (CAS 120685-11-2)  Product Citations

See how others have used PKC-412 (CAS 120685-11-2). Click on the entry to view the PubMed entry .

Citations 1 to 8 of 8 total

PMID: # 28403213  Hara, Y. et al. 2017. PLoS ONE. 12: e0175514.

PMID: # 28506695  Omori, I. et al. 2017. Exp. Hematol. 52: 56-64.e4.

PMID: # 28192400  Obata, Y. et al. 2017. Oncogene. 36: 3661-3672.

PMID: # 26771236  Fox, JM. et al. 2016. Oncotarget. 7: 7268-79.

PMID: # 27543462  Sulen, A. et al. 2016. Pharmacol. Res. 113: 216-227.

PMID: # 26104663  Peng, X. et al. 2015. Leukemia. 29: 2355-65.

PMID: # 24735609  Yoshida, A. et al. 2014. Biochem. Pharmacol. 90: 16-24.

PMID: # 25493654  Obata, Y. et al. 2014. Nat Commun. 5: 5715.

Citations 1 to 8 of 8 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 118ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Chen et al Chen et al. (PubMed ID 16091734) found that treatment of hematopoietic malignancies with the tyrosine kinase inhibitor, PKC-412, prevented the proliferation of hematopoietic Ba/F3 cells via FGFR3 regulation. -SCBT Publication Review
Date published: 2015-06-16
  • y_2021, m_7, d_26, h_19
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.18
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_200691, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 15ms
  • REVIEWS, PRODUCT